Challenging patient population
Unlike other OTC products that are tested in mild short-term pain, PainPause was evaluated in patients with difficult to treat chronic musculoskeletal conditions and high levels of pain.
CLINICAL EVIDENCE
PainPause was evaluated in a clinical study of 37 patients with moderate-to-severe chronic low back pain, sciatica, knee pain, and thoracic/shoulder pain. Each patient received a single treatment with the product. The average level of their pain decreased by more than 50% over the week of the study. Over 70% of patients experienced clinically significant pain relief that lasted for 7 days.
Average of Pain Scores of All Patients
(Days 0-7)
Pain Scores (Scale of 0-10)
Challenging patient population
Unlike other OTC products that are tested in mild short-term pain, PainPause was evaluated in patients with difficult to treat chronic musculoskeletal conditions and high levels of pain.
Clinically relevant endpoint: 7-day duration of pain relief
The study monitored pain levels for one week. This contrasts with most OTC pain relief products that are short acting with pain relief measured for a few hours.
Adults of all ages including seniors
Safe and effective across a wide age range of people, and can be used in those with chronic medical conditions affecting the heart, kidneys, lungs, liver, and other organs.
Rapid onset of pain relief
Some patients reported less pain within minutes of application. Others within a few hours. Continuous pain relief while the patch was worn and even for days after device removal in some patients.
CLINICAL STUDY
The complete clinical study opens on this page. If it does not display below, use the download link.